Interactions on record — worth a quick check against your medications. Based on 8 of 11 ingredients. Check your meds →
Dietary supplement

Master Blend Mushrooms & Adaptogens Ingredients & Drug Interactions

by Om Mushroom Superfood

Capsule Category: Botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Master Blend Mushrooms & Adaptogens is a dietary supplement by Om Mushroom Superfood with 11 active ingredients. Its ingredients are commonly taken for immune support, general wellness and nutrition, cholesterol and heart health.Based on those ingredients, 1,449 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are KSM-66, Reishi, Powder, Lion's Mane, Powder. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 1 of its 11 active ingredients.
  • “Certified Organic Mushroom Powder Blend” is a proprietary blend — the label gives one combined amount (2 Gram(s)) without saying how much of each component you get.

This product contains 11 active ingredients: six medicinal mushroom powders (shiitake, lion's mane, cordyceps, reishi, maitake, and chaga), one branded mushroom blend listed as a group (himematsutake, which is another name for agaricus), three others we could not check the data for (a certified organic mushroom powder blend, turkey tail, and antrodia), and ashwagandha (KSM-66), an adaptogenic herb. Each mushroom and herb plays its own role — some are traditionally used to support immune function, others for stress or relaxation.

The capsules also contain cellulose as an inactive ingredient.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: adaptogen for stress relief immune health.
  • We looked for evidence on: Anxiety, Generalized anxiety disorder (GAD), Fatigue, Chronic fatigue syndrome (CFS), Cancer-related fatigue, Chemotherapy-related fatigue — and 4 related terms.
  • The strongest evidence on file: Ashwagandha is rated "Possibly Effective" for Anxiety (Natural Medicines).
  • Also on file: Ashwagandha is rated "Possibly Effective" for Generalized anxiety disorder (GAD).
  • Also on file: Maitake Mushroom is rated "Insufficient Reliable Evidence To Rate" for Chronic fatigue syndrome (CFS), Chemotherapy-related fatigue, Coronavirus disease 2019 (COVID-19).

The data we hold doesn't establish that these ingredients are effective for any single condition. For ashwagandha specifically, there is possibly effective evidence for insomnia, anxiety, generalized anxiety disorder (GAD), and stress — those are the only effectiveness claims supported by the data for this product.

For the mushrooms — shiitake, lion's mane, cordyceps, reishi, agaricus (himematsutake), maitake, and chaga — the evidence is insufficient to rate them for the conditions that have been studied. That doesn't mean they don't work; it means the research so far isn't conclusive enough to say one way or the other.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 8 of the 8 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 7 of 8.
  • General safety write-ups exist for 8 of 8.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Most of these ingredients are generally well tolerated when used short-term. The most common side effects are gastrointestinal — stomach discomfort, bloating, diarrhea, nausea, and vomiting.

Ashwagandha, lion's mane, cordyceps, reishi, agaricus, maitake, and chaga all carry some caution flags. Ashwagandha in rare cases has been linked to serious liver damage, and there are case reports of ashwagandha causing hyperthyroidism, drowsiness, and in one instance intracranial bleeding (though the exact link is unclear).

Raw or uncooked shiitake can cause a rash called shiitake dermatitis. Long-term safety data are limited for most of these mushrooms and for ashwagandha.

Chaga, when taken in very high amounts, contains oxalate and has been associated with kidney problems in a few cases. If you're allergic to mushrooms or have respiratory sensitivities, handle these powders with care — spore inhalation can trigger allergic reactions.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 8 of the 8 matched ingredients can interact with medications — Maitake Mushroom, Cordyceps, Shiitake Mushroom, Reishi Mushroom, Ashwagandha, among others.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,450 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check with your pharmacist if you take blood thinners or antiplatelet drugs (aspirin, warfarin, clopidogrel), diabetes medications, blood pressure medications, sedatives or benzodiazepines, any drug that suppresses your immune system, thyroid hormone, or any medication processed by liver enzymes. The highest-concern interactions are with hepatotoxic drugs (drugs that can damage the liver) and ashwagandha, and with blood thinners and multiple mushroom ingredients.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This blend mixes six mushroom powders with ashwagandha, an adaptogenic herb with some research backing for stress and sleep. It's generally well tolerated short-term, but if you take any medications — especially blood thinners, diabetes drugs, blood pressure medications, sedatives, immune suppressors, or thyroid hormone — you need to check your specific medications against this product before starting.

Talk to your pharmacist or doctor first, especially if you have liver problems or are pregnant or breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 9 of 11 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Oct 24, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Master Blend Mushrooms & Adaptogens, straight from the product label.

Brand Om Mushroom Superfood
Barcode (UPC) 850011996720
Net contents 84 Vegetable Capsule(s)
Market status On market
Date entered into DSLD Oct 24, 2024
DSLD ID 318049
Product type Botanical
Supplement form Capsule
Dietary claims / uses Nutrient, All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Kosher, Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
3 Capsule(s)
Maximum serving Sizes:
3 Capsule(s)
Servings per container
28
UPC/BARCODE
850011996720
IngredientAmount% DV
Shiitake, Powder0 NP--
Certified Organic Mushroom Powder Blend2 Gram(s)--
Lion's Mane, Powder0 NP--
Cordyceps, Powder0 NP--
Reishi, Powder0 NP--
Himematsutake, Powder0 NP--
Maitake, Powder0 NP--
King Trumpet, Powder0 NP--
Turkey Tail, Powder0 NP--
Chaga, Powder0 NP--
Antrodia, Powder0 NP--
KSM-66250 mg--

Other ingredients: Cellulose

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Adaptogen powerhouse Supercharge your daily health with this curated blend of 10 species of USA grown, whole food mushroom powder. Also included is 250mg of KSM-66, a potent full-spectrum Ashwagandha root extract that helps improve resistance toward stress.

Grown on whole oats or sorghum, which provide nutritious "food" for the mushroom mycelium. After completing its lifecycle, we dry everything the mycelium and fruiting bodies together and nothing gets left behind. Our minimally processed, full-lifecycle mushrooms provide a full spectrum of active compounds to support optimal health.

Beta glucans and prebiotics

Superfood Beta Glucans 10 Mushrooms 250mg Ashwagandha Per serving

EarthKosher Certified Kosher by Earth Kosher

Formulation

It's a powerful master blend for vibrant health. Gut health Immune defense Stress relief Antioxidants We grow our OM 10 mushroom species in our organic indoor farm in California.

No filler! No extracts Tested for heavy metals

Whole food nutrition

Non GMO Project Verified nongmoproject.org

Helps Support: Immune health Vitality Stress relief Daily boost capsules

Gf Gluten free

V Vegan

General Statements

Scan code to learn more

28 Day Supply

Facebook Instagram @OmMushrooms OmMushrooms.com

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Seals/Symbols

Non GMO Project Verified nongmoproject.org

EarthKosher Certified Kosher by Earth Kosher

FDA Statement of Identity

Dietary Supplement

Suggested/Recommended/Usage/Directions

Suggested Use: Take three (3) capsules per day with a glass of water. Take as directed.

Precautions

If you have a medical condition, are on medication or are pregnant or nursing, please seek the direction of a qualified health care professional before using.

Keep out of reach of children.

Storage

Store in a cool, dry place.

See for yourself

Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood

These are the 11 active ingredients this product is made of. Select any to open its full monograph.

Serving size3 Capsule(s) Dosage formCapsule Servings per container28 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Certified Organic Mushroom Powder Blend

2 Gram(s) per serving

KSM-66

Interacts with
1,372 drugs
250 mg per serving Form: Ashwagandha Root Extract

Ashwagandha is an Ayurvedic herb most often taken to help with stress, anxiety, and sleep, and some small studies suggest it may help, though the evid...

KSM-66 monograph & interactions

Other (inactive) ingredients: Cellulose. These complete the product’s ingredient list but are not active constituents.

Interaction report

Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood Drug Interactions

Want to check YOUR meds against Master Blend Mushrooms & Adaptogens?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,449Drugs
1,079 Moderate 370 Minor

Ingredients driving the most interactions

KSM-66 1,372

Each ingredient & the kinds of drugs it affects

For each ingredient in Master Blend Mushrooms & Adaptogens with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

KSM-6610 drug types · 1,372 drugs

Antidiabetes Drugs

Theoretically, taking ashwagandha with antidiabetes drugs might increase the risk of hypoglycemia.
There is preliminary clinical evidence suggesting that ashwagandha might lower blood glucose levels. Theoretically, ashwagandha might have additive effects when used with antidiabetes drugs and increase the risk of hypoglycemia.

Likelihood Possible Evidence B
Antihypertensive Drugs

Theoretically, taking ashwagandha with antihypertensive drugs might increase the risk of hypotension.
Animal research suggests that ashwagandha might lower systolic and diastolic blood pressure. Theoretically, ashwagandha might have additive effects when used with antihypertensive drugs and increase the risk of hypotension.

Likelihood Possible Evidence D
Benzodiazepines

Theoretically, taking ashwagandha might increase the sedative effects of benzodiazepines.
There is preliminary evidence that ashwagandha might have an additive effect with diazepam (Valium) and clonazepam (Klonopin). This may also occur with other benzodiazepines.

Likelihood Possible Evidence D
Cns Depressants

Theoretically, taking ashwagandha might increase the sedative effects of CNS depressants.
Ashwagandha seems to have sedative effects. Theoretically, this may potentiate the effects of barbiturates, other sedatives, and anxiolytics.

Likelihood Possible Evidence D
Hepatotoxic Drugs

Theoretically, taking ashwagandha with hepatotoxic drugs might increase the risk of liver damage.
Ashwagandha has been linked to cases of acute hepatitis, liver failure, hepatic encephalopathy, autoimmune hepatitis, the need for liver transplantation, and death due to liver failure.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, taking ashwagandha might decrease the effects of immunosuppressants.
Ashwagandha has demonstrated immunostimulant effects in humans. Animal research has shown that ashwagandha can attenuate the immunosuppression caused by cyclophosphamide.

Likelihood Possible Evidence D
Thyroid Hormone

Ashwagandha might increase the effects and adverse effects of thyroid hormone.
Concomitant use of ashwagandha with thyroid hormones may cause additive therapeutic and adverse effects. Preliminary clinical research and animal studies suggest that ashwagandha boosts thyroid hormone synthesis and secretion. In one clinical study, ashwagandha increased triiodothyronine (T3) and thyroxine (T4) levels by 41.5% and 19.6%, respectively, and reduced serum TSH levels by 17.4% from baseline in adults with subclinical hypothyroidism.

Likelihood Probable Evidence B
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, ashwagandha might decrease the levels and clinical effects of CYP1A2 substrates.
In vitro research shows that ashwagandha extract induces CYP1A2 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, ashwagandha might decrease the levels and clinical effects of CYP3A4 substrates.
In vitro research shows that ashwagandha extract induces CYP3A4 enzymes.

Likelihood Possible Evidence D
Serotonergic Drugs

Some animal studies have reported that ashwagandha can enhance serotonergic transmission by altering certain serotonin (5-HT) receptors. However, there is no evidence to suggest that ashwagandha increases the risk of serotonin-related effects, and there have been no published case reports of serotonin syndrome when combined with other serotonergic drugs. Nevertheless, due to the lack of extensive studies on the matter and the fact that ashwagandha appears to affect serotonergic pathways, it would be prudent to exercise caution when combining it with drugs that affect serotonin. [References: - Effects of Withania somnifera (Ashwaga ndha) on Stress and the Stress-Related Neuropsychiatric Disorders Anxiety, Depression, and Insomnia. Curr Neuropharmacol. 2021 Sep 14; 19: 1468–1495. - A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573577/]

Likelihood Possible Evidence C

Reishi, Powder3 drug types · 375 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, high doses of reishi mushroom might increase the risk of bleeding.
A dose of 1.5 grams daily of reishi mushroom does not seem to decrease platelet aggregation, but a higher dose of 3 grams daily does.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, reishi mushroom might have additive effects with antidiabetes drugs.
Animal research suggests that reishi mushroom decreases blood sugar. However, in patients with type 2 diabetes, taking reishi mushroom does not reduce fasting glucose levels, and its effects on glycated hemoglobin are inconsistent.

Likelihood Possible Evidence D
Antihypertensive Drugs

Theoretically, concurrent use of reishi mushroom with antihypertensive drugs might increase the risk of hypotension.
Reishi mushroom has shown hypotensive activity in animal research. Clinical evidence suggests that reishi mushroom reduces blood pressure in some, but not all, patients with hypertension.

Likelihood Possible Evidence D

Lion's Mane, Powder3 drug types · 327 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, lion's mane mushroom may increase the risk of bleeding when used with anticoagulant/antiplatelet drugs.
In vitro research suggests that lion's mane mushroom extracts can inhibit platelet aggregation.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, lion's mane mushroom may have additive effects when used with antidiabetes drugs.
Animal research suggests that an aqueous extract of lion's mane mushroom can reduce serum glucose and increase serum insulin.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, concurrent use of lion's mane mushroom might interfere with immunosuppressive therapy.
In animal and in vitro research, lion's mane mushroom polysaccharides stimulate the immune system.

Likelihood Possible Evidence D

Chaga, Powder3 drug types · 327 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, chaga may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
In vitro and animal research suggests that chaga extract can inhibit platelet aggregation. This effect has not been reported in humans.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, taking chaga with antidiabetes drugs might increase the risk of hypoglycemia.
Animal research suggests that chaga might decrease blood glucose levels and increase insulin levels. This has not been reported in humans.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, chaga might interfere with immunosuppressive therapy.
In vitro research suggests that certain constituents of chaga stimulate immune function. This has not been reported in humans.

Likelihood Possible Evidence D

Shiitake, Powder2 drug types · 312 drugs

Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, shiitake mushroom might decrease levels of drugs metabolized by CYP2D6.
In vitro studies suggest that the shiitake mushroom extract AHCC might induce the CYP2D6 enzyme. This effect has not been reported in humans.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, taking shiitake mushroom might decrease the effects of immunosuppressive therapy.
In vitro evidence suggests that shiitake mushroom extracts stimulate immune function.

Likelihood Possible Evidence D

Maitake, Powder3 drug types · 260 drugs

Antidiabetes Drugs

Theoretically, combining maitake mushroom with antidiabetes drugs might increase the risk of hypoglycemia.
Clinical research shows that taking maitake mushroom polysaccharide (MMP) can lower blood glucose levels in patients with types 2 diabetes.

Likelihood Possible Evidence B
Antihypertensive Drugs

Theoretically, combining maitake mushroom with antihypertensive drugs might increase the risk of hypotension.
Animal research shows that maitake mushroom can lower blood pressure.

Likelihood Possible Evidence D
Warfarin (Coumadin)

There is limited evidence that maitake mushroom may increase the anticoagulant effects of warfarin.
In a case report, a patient previously stabilized on warfarin developed an elevated international normalized ratio (INR) of 5.1 after taking maitake mushroom (Grifron-Pro Maitake D-Fraction) 1 drop/kg daily in three divided doses for one week. The elevated INR resolved after holding warfarin for two days, then reducing the dose by 11%. It is thought that the beta-glucan constituent of maitake mushroom might cause warfarin dissociation from proteins, resulting in increased free warfarin levels and increased warfarin effects.

Likelihood Possible Evidence D

Cordyceps, Powder3 drug types · 249 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, cordyceps may increase the risk of bleeding when used with antiplatelet or anticoagulant drugs.
In vitro and animal research suggests that cordyceps extract inhibits platelet aggregation and function. However, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, concurrent use of cordyceps might interfere with immunosuppressive therapy.
Animal and in vitro research suggests that cordyceps stimulates the immune system. However, limited clinical research suggests that taking cordyceps may lower the necessary therapeutic dose of the immunosuppressant cyclosporine, which suggests that cordyceps may have an immunosuppressive effect.

Likelihood Possible Evidence B
Testosterone

Theoretically, concurrent use of cordyceps and testosterone might have additive effects.
Animal research suggests that cordyceps can increase testosterone levels. The clinical significance of this finding is unclear.

Likelihood Possible Evidence D

Himematsutake, Powder1 drug type · 86 drugs

Antidiabetes Drugs

Theoretically, taking agaricus mushroom with antidiabetes drugs might increase the risk of hypoglycemia.
In one clinical study in patients with type 2 diabetes who are stabilized on conventional oral hypoglycemic agents, 3 of 29 patients taking an agaricus mushroom extract 500 mg three times daily for 12 weeks reported hypoglycemia, compared to one of 29 patients in the placebo group.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Master Blend Mushrooms & Adaptogens, from the product label.

Om Mushroom Superfood

See all Om Mushroom Superfood products
Name
Om Mushroom Superfood
City
Carlsbad
State
CA
Web Address
OmMushrooms.com
Pharmacist Counseling Corner

Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood: Common Questions

Does Master Blend Mushrooms & Adaptogens by Om Mushroom Superfood interact with any medications?
Yes. Based on its ingredients, Master Blend Mushrooms & Adaptogens has a known interaction with 1,449 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Master Blend Mushrooms & Adaptogens contains 11 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Does this product actually work for stress and sleep?
Ashwagandha in this blend has possibly effective evidence for insomnia, anxiety, and stress — so there's research suggesting it may help. The mushrooms don't have enough evidence yet to claim they work for specific conditions. Your results will depend on your individual situation and the dose.
Can I take this if I'm pregnant or breastfeeding?
No. Ashwagandha is traditionally thought to risk miscarriage, and lion's mane, cordyceps, reishi, agaricus, maitake, and chaga don't have enough safety data during pregnancy and breastfeeding — the safety notes advise against it. Talk to your OB or pharmacist about what's safe for you.
What's the most common side effect?
Stomach upset — bloating, diarrhea, nausea, or abdominal discomfort. These are usually mild and can sometimes be reduced by taking the capsules with food.
What are the mushrooms in here, and what do they do?
You're getting shiitake, lion's mane, cordyceps, reishi, maitake, chaga, and agaricus (labeled as himematsutake). Traditionally, these are used to support immune function, energy, and overall wellness, though the research is still catching up on whether they do what people claim for specific conditions.
Are there any fillers or weird ingredients?
The only inactive ingredient is cellulose, which is a binder used in most capsules. That's a pretty clean formula — no sketchy additives listed.
I'm on a blood thinner — is this safe for me?
You need to talk to your pharmacist or doctor before taking this. Lion's mane, cordyceps, reishi, chaga, and maitake all theoretically increase bleeding risk, and one case report linked maitake to a dangerous rise in warfarin levels. Don't start without checking with your doctor.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Master Blend Mushrooms & Adaptogens is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Master Blend Mushrooms & Adaptogens label
Go deeper

The Full Monographs Behind Master Blend Mushrooms & Adaptogens’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Shiitake Mushroom

Interacts with 312 drugs

Shiitake is a popular edible mushroom that is nutritious and safe to eat as food for most people. Some of its extracts (like lentinan and AHCC) have been studied as immune support, mainly al...

Read the full Shiitake Mushroom monograph →
Herb & supplement monograph

Lion's Mane Mushroom

Interacts with 327 drugs

Lion's mane is an edible mushroom that is popular as a 'nootropic' for memory, focus, and nerve health, but solid human evidence is still limited and early. It is generally well tolerated as...

Read the full Lion's Mane Mushroom monograph →
Herb & supplement monograph

Cordyceps

Interacts with 249 drugs

Cordyceps is a fungus used in traditional Chinese medicine for energy, exercise performance, and lung and immune support. Human research is limited and mostly low quality, so its benefits ar...

Read the full Cordyceps monograph →
Herb & supplement monograph

Reishi Mushroom

Interacts with 375 drugs

Reishi is a traditional Asian mushroom widely used to support the immune system and overall wellness. Human evidence for most of its claimed benefits is limited or low-quality, so it should...

Read the full Reishi Mushroom monograph →
Herb & supplement monograph

Agaricus Mushroom

Interacts with 86 drugs

Agaricus mushroom (often Agaricus blazei/subrufescens) is a culinary and medicinal mushroom studied mostly for possible immune and antioxidant effects. The human evidence is limited and not...

Read the full Agaricus Mushroom monograph →
Herb & supplement monograph

Maitake Mushroom

Interacts with 260 drugs

Maitake is an edible mushroom long used as food and in traditional Japanese medicine, and it is being studied for possible immune, blood sugar, and blood pressure effects. The human evidence...

Read the full Maitake Mushroom monograph →
Herb & supplement monograph

Chaga

Interacts with 327 drugs

Chaga is a fungus that grows mostly on birch trees and is used as a tea or supplement, mainly for immune and antioxidant support. Human evidence for its benefits is very limited, and it may...

Read the full Chaga monograph →
Herb & supplement monograph

Ashwagandha

Interacts with 1,372 drugs

Ashwagandha is an Ayurvedic herb most often taken to help with stress, anxiety, and sleep, and some small studies suggest it may help, though the evidence is still limited. It is generally w...

Read the full Ashwagandha monograph →
Sources

Sources & How We Checked

Master Blend Mushrooms & Adaptogens's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 158 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Shiitake Mushroom 67 references
  1. Hitosugi M, Kitamura O, Takatsu A, Yoshino Y. Autopsy case of duodenal obstruction from impacted mushroom. J Gastroenterol 1998;33:562-5. PubMed
  2. Hanada K, Hashimoto I. Flagellate mushroom (Shiitake) dermatitis and photosensitivity. Dermatol 1998;197:255-7. PubMed
  3. Levy AM, Kita H, Phillips SF, et al. Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms. J Allergy Clin Immunol 1998;101:613-20. PubMed
  4. Murakami M, Kawabe K, Hosoi Y, et al. Decreased pulmonary perfusion in hypersensitivity pneumonitis caused by Shiitake mushroom spores. J Intern Med 1997;241:85-8. PubMed
  5. Matsui S, Nakazawa T, Umegae Y, Mori M. Hypersensitivity pneumonitis induced by Shiitake mushroom spores. Intern Med 1992;31:1204-6.
  6. Nakamura T. Shiitake (Lentinus edodes) dermatitis. Contact Dermatitis 1992;27:65-70.
  7. Ueda A, Obama K, Aoyama K, et al. Allergic contact dermatitis in shiitake (Lentinus edodes (Berk) Sing) growers. Contact Dermatitis 1992;26:228-33.
  8. Burikhanov, R. B., Wakame, K., Igarashi, Y., Wang, S., and Matsuzaki, S. Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat. Endocr.Regul. 2000;34(4):181-188.
  9. Gao, Y., Zhang, D., Sun, B., Fujii, H., Kosuna, K., and Yin, Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol.Immunother. 2006;55(10):1258-1266. PubMed
  10. Ritz, B. W., Nogusa, S., Ackerman, E. A., and Gardner, E. M. Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection. J Nutr. 2006;136(11):2868-2873. PubMed
  11. Aviles, H., O'Donnell, P., Sun, B., and Sonnenfeld, G. Active hexose correlated compound (AHCC) enhances resistance to infection in a mouse model of surgical wound infection. Surg.Infect.(Larchmt.) 2006;7(6):527-535. PubMed
  12. Spierings, E. L., Fujii, H., Sun, B., and Walshe, T. A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol.(Tokyo) 2007;53(6):536-539. PubMed
  13. Aviles, H., O'Donnell, P., Orshal, J., Fujii, H., Sun, B., and Sonnenfeld, G. Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection. Am J Surg. 2008;195(4):537-545. PubMed
  14. Ritz, B. W. Supplementation with active hexose correlated compound increases survival following infectious challenge in mice. Nutr.Rev. 2008;66(9):526-531. PubMed
  15. Terakawa, N., Matsui, Y., Satoi, S., Yanagimoto, H., Takahashi, K., Yamamoto, T., Yamao, J., Takai, S., Kwon, A. H., and Kamiyama, Y. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controll
  16. Mach, C. M., Fugii, H., Wakame, K., and Smith, J. Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soc Integr.Oncol. 2008;6(3):105-109.
  17. Wang, S., Welte, T., Fang, H., Chang, G. J., Born, W. K., O'Brien, R. L., Sun, B., Fujii, H., Kosuna, K., and Wang, T. Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr. 2009;139(3 PubMed
  18. Sumiyoshi, Y., Hashine, K., Kakehi, Y., Yoshimura, K., Satou, T., Kuruma, H., Namiki, S., and Shinohara, N. Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study. Jpn.J Cl PubMed
  19. Yin, Z., Fujii, H., and Walshe, T. Effects of active hexose correlated compound on frequency of CD4+ and CD8+ T cells producing interferon-gamma and/or tumor necrosis factor-alpha in healthy adults. Hum.Immunol. 2010;71(12):1187-1190.
  20. Lee, W. W., Lee, N., Fujii, H., and Kang, I. Active Hexose Correlated Compound promotes T helper (Th) 17 and 1 cell responses via inducing IL-1beta production from monocytes in humans. Cell Immunol. 2012;275(1-2):19-23.
  21. Daddaoua, A., Martinez-Plata, E., Ortega-Gonzalez, M., Ocon, B., Aranda, C. J., Zarzuelo, A., Suarez, M. D., de Medina, F. S., and Martinez-Augustin, O. The nutritional supplement Active Hexose Correlated Compound (AHCC) has direct immunomodulatory actio
  22. Roman, B. E., Beli, E., Duriancik, D. M., and Gardner, E. M. Short-term supplementation with active hexose correlated compound improves the antibody response to influenza B vaccine. Nutr Res. 2013;33(1):12-17. PubMed
  23. Uno, K., Kosuna, K., Sun, B., Fujii, H., Wakame, K., Chikumaru, S., Hosokawa, G., and Ueda, Y. Active Hexose Correlated Compound (AHCC) Improves Immunological Parameters and Performance Status of Patients with Solid Tumors. Biotherapy 2000;14(3):303-309.
  24. Ghoneum, M., Wimbley, M., Salem, F., McKlain, A., Attallah, N., and Gill, G. Immunomodulatory and anticancer effects of active hexose correlated compound (AHCC). Int J Immunother 1995;11:23-28.
  25. Thaiudom, S., Piyaniran, W., and Chutaputthi, A. A study of the efficacy of Active Hexose Correlated Compound (AHCC) in the treatment of chronic Hepatitis C patients at Phramongkutklao Hospital. The Medical News (Thailand) 2010;325:13-16.
  26. Smith, J. A., Hunter, R. J., Fujii, H., Wakame, K., and Wolf, J. Defining Synergistic Activity ofthe Combination of Active Hexose Correlated Compound (AHCC) with Liposomal Doxorubicin (Doxil). Presented at the 18th International Congress on Nutrition and
  27. Sia, G. M. and Candlish, J. K. Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line. Phytother.Res. 1999;13(2):133-137. DOI
  28. Fujiwara, K., Sato, T., Yonei, T., Genba, K., Nogami, N., and Yamadori, I. [A case of chronic hypersensitivity pneumonitis induced by shiitake mushroom spores]. Nihon Kokyuki.Gakkai Zasshi 2000;38(12):908-913.
  29. Lippert, U., Martin, V., Schwertfeger, C., Junghans, V., Ellinghaus, B., and Fuchs, T. Shiitake dermatitis. Br.J Dermatol. 2003;148(1):178-179.
  30. Lobanok, A. G., Babitskaia, V. G., Plenina, L. V., Puchkova, T. A., and Osadchaia, O. V. [Composition and biological activity of submerged mycelium of the xylotrophic basidiomycete Lentinus edodes]. Prikl.Biokhim.Mikrobiol. 2003;39(1):69-73. DOI
  31. Curnow, P. and Tam, M. Contact dermatitis to Shiitake mushroom. Australas.J.Dermatol. 2003;44(2):155-157. PubMed
  32. Mak, R. K. and Wakelin, S. H. Shiitake dermatitis: the first case reported from a European country. Br J Dermatol 2006;154(4):800-801. PubMed
  33. Sastre, J., Ibanez, M. D., Lopez, M., and Lehrer, S. B. Respiratory and immunological reactions among Shiitake (Lentinus edodes) mushroom workers. Clin.Exp.Allergy 1990;20(1):13-19.
  34. Liu, M., Li, J., Kong, F., Lin, J., and Gao, Y. Induction of immunomodulating cytokines by a new polysaccharide-peptide complex from culture mycelia of Lentinus edodes. Immunopharmacology 1998;40(3):187-198. PubMed
  35. Ade R, Sukut C, Wiser HJ, Shockman S, Buescher L. Shiitake dermatitis demonstrating Köebner phenomenon. Int J Dermatol. 2015;54(5):e179-81.
  36. Adler MJ, Larsen WG. Clinical variability of shiitake dermatitis. J Am Acad Dermatol. 2012 Oct;67(4):e140-1. PubMed
  37. Adriano AR, Acosta ML, Azulay DR, Quiroz CD, Talarico SR. Shiitake dermatitis: the first case reported in Brazil. An Bras Dermatol. 2013 May-Jun;88(3):417-9. PubMed
  38. Ampere A, Delhaes L, Soots J, Bart F, Wallaert B. Hypersensitivity pneumonitis induced by Shiitake mushroom spores. Med Mycol. 2012 Aug;50(6):654-7. PubMed
  39. Baran W, Batycka-Baran A, Maj J, Szepietowski JC. Shiitake dermatitis - now also in Poland. Acta Derm Venereol. 2015 Jan;95(1):102-3. PubMed
  40. Boels D, Landreau A, Bruneau C, et al. Shiitake dermatitis recorded by French Poison Control Centers - new case series with clinical observations. Clin Toxicol (Phila). 2014 Jul;52(6):625-8. PubMed
  41. Chu EY, Anand D, Dawn A, Elenitsas R, Adler DJ. Shiitake dermatitis: a report of 3 cases and review of the literature. Cutis. 2013 Jun;91(6):287-90.
  42. Corazza M, Zauli S, Ricci M, et al. Shiitake dermatitis: toxic or allergic reaction? J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1449-51. PubMed
  43. Czarnecka AB, Kreft B, Marsch WCh. Flagellate dermatitis after consumption of Shiitake mushrooms. Postepy Dermatol Alergol. 2014 Jun;31(3):187-90. PubMed
  44. Dai X, Stanilka JM, Rowe CA, et al. Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults. J Am Coll Nutr. 2015;34(6):478-87.
  45. Hamer SE, Kulkarni K, Cohen SN. Shiitake dermatitis with oral ulceration and pustules. Clin Exp Dermatol. 2015 Apr;40(3):332-3. PubMed
  46. Hiernickel C, Metz S, Elsner P. Shiitake dermatitis: an impressive case report. J Dtsch Dermatol Ges. 2015 May;13(5):455-6. PubMed
  47. Karanovic S, George S, Topham E. Don't miss shiitake dermatitis: a case report. Br J Gen Pract. 2014 Aug;64(625):426-7. PubMed
  48. Kopp T, Mastan P, Mothes N, Tzaneva S, Stingl G, Tanew A. Systemic allergic contact dermatitis due to consumption of raw shiitake mushroom. Clin Exp Dermatol. 2009 Dec;34(8):e910-3. PubMed
  49. Lingström P, Zaura E, Hassan H, et al. The anticaries effect of a food extract (shiitake) in a short-term clinical study. J Biomed Biotechnol. 2012;2012:217164. PubMed
  50. Loo HV, Oon HH. Flagellate dermatitis following consumption of shiitake mushroom. Dermatol Reports. 2011 Oct 5;3(2):e21. PubMed
  51. Luber AJ, Ackerman LS. Flagellate shiitake mushroom dermatitis. Dermatol Online J. 2015 Aug 15;21(8). pii: 13030/qt7rm57553. DOI
  52. Mendonça CN, Silva PM, Avelleira JC, Nishimori FS, Cassia Fde F. Shiitake dermatitis. An Bras Dermatol. 2015 Mar-Apr;90(2):276-8.
  53. Netchiporouk E, Pehr K, Ben-Shoshan M, Billick RC, Sasseville D, Singer M. Pustular flagellate dermatitis after consumption of shiitake mushrooms. JAAD Case Rep. 2015 May 2;1(3):117-9. PubMed
  54. Nguyen AH, Gonzaga MI, Lim VM, Adler MJ, Mitkov MV, Cappel MA. Clinical features of shiitake dermatitis: a systematic review. Int J Dermatol. 2017 Jun;56(6):610-616. PubMed
  55. Poppe LM, Anders D, Kneitz H, Bröcker EB, Benoit S. Flagellate dermatitis caused by shiitake mushrooms. An Bras Dermatol. 2012 May-Jun;87(3):463-5. PubMed
  56. Pravettoni V, Primavesi L, Piantanida M. Shiitake mushroom (Lentinus edodes): a poorly known allergen in Western countries responsible for severe work-related asthma. Int J Occup Med Environ Health. 2014 Oct;27(5):871-4. PubMed
  57. Ricar J, Pizinger K, Cetkovska P. Shiitake dermatitis: a distinctive clinical entity. Int J Dermatol. 2013 Dec;52(12):1620-1. PubMed
  58. Shozushima M, Ohata K, Nonaka K, Matsuhashi N. Shiitake mushroom-induced ileus managed using double-balloon enteroscopy. Endoscopy. 2013;45 Suppl 2 UCTN:E437. PubMed
  59. Uslu U, Linkner RV. Shiitake mushroom dermatitis. Cutis. 2015 May;95(5):E11-2.
  60. Wang AS, Barr KL, Jagdeo J. Shiitake mushroom-induced flagellate erythema: A striking case and review of the literature. Dermatol Online J. 2013 Apr 15;19(4):5. DOI
  61. Tan J, Yuan K, Zuo J, et al. Two cases of small bowel obstruction due to a shiitake mushroom. Gastroenterol Rep (Oxf) 2019;7(4):298-300. doi: 10.1093/gastro/gox028. PubMed
  62. Boels D, Greillet C, Langrand J, et al. Shiitake dermatitis: experience of the Poison Control Centre Network in France from 2014 to 2019. Clin Toxicol (Phila) 2022. PubMed
  63. Miyagishima D, Inoue M, Kinjo K, et al. A case of bowel obstruction due to shiitake mushrooms: Diagnostic features on computed tomography. Intern Med 2022. PubMed
  64. Soga K, Mukai H, Kitae H. Management of shiitake mushroom-induced ileus using balloon enteroscopy. Dig Endosc 2022;34(4):e58-e59. PubMed
  65. Ma JY, Liu JW. Shiitake flagellate dermatitis. Mayo Clin Proc 2022;97(12):2192-2193. PubMed
  66. Booms A, Rashid Z, Al-Rubaie V, Bal A. Shiitake dermatitis: a case report of a rare mushroom-induced dermatitis in the United States. Int J Dermatol 2022. PubMed
  67. Sudy E, Urbina F. Shiitake dermatitis: clinical forms of presentation. Int J Dermatol 2023. PubMed

See these in context on the Shiitake Mushroom monograph →

Lion's Mane Mushroom 6 references
  1. Product information for <em>Niaspan</em>. Abbott Laboratories. North Chicago, IL 60064. April 2015.
  2. Liang B, Guo Z, Xie F, Zhao A. Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium erinaceus in experimental diabetic rats. BMC Complement Altern Med. 2013;13:253. PubMed
  3. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-72.
  4. Mori K, Kikuchi H, Obara Y, et al. Inhibitory effect of hericenone B from Hericium erinaceus on collagen-induced platelet aggregation. Phytomedicine. 2010;17(14):1082-5. PubMed
  5. Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci 2020 Jun 3;12:155. doi: 10.3389/fnagi.2020.00155. PubMed
  6. Tian B, Liu R, Xu T, et al. Modulating effects of Hericium erinaceus polysaccharides on the immune response by regulating gut microbiota in cyclophosphamide-treated mice. J Sci Food Agric 2023;103(6):3050-3064.

See these in context on the Lion's Mane Mushroom monograph →

Cordyceps 14 references
  1. Zhu JS, Halpern GM, Jones K. The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis: part I. J Altern Complement Med 1998;4:289-303.
  2. Zhu JS, Halpern GM, Jones K. The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis: part II. J Altern Complement Med 1998;4:429-57.
  3. Chen YJ, Shiao MS, Lee SS, Wang SY. Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells. Life Sci 1997;60:2349-59. PubMed
  4. Zhao Y. [Inhibitory effects of alcoholic extract of Cordyceps sinensis on abdominal aortic thrombus formation in rabbits]. Chung Hua I Hsueh Tsa Chih (Taipei) 1991;71:612-5, 42.
  5. Chen GZ, Chen GL, Sun T, et al. Effects of Cordyceps sinensis on murine T lymphocyte subsets. Chin Med J (English) 1991;104:4-8.
  6. Zhu XY, Yu HY. [Immunosuppressive effect of cultured Cordyceps sinensis on cellular immune response]. Chung Hsi I Chieh Ho Tsa Chih 1990;10:485-7, 454.
  7. Hsu, C. C., Huang, Y. L., Tsai, S. J., Sheu, C. C., and Huang, B. M. In vivo and in vitro stimulatory effects of Cordyceps sinensis on testosterone production in mouse Leydig cells. Life Sci 9-5-2003;73(16):2127-2136. PubMed
  8. Ikumoto, T., Sasaki, S., Namba, H., Toyama, R., Moritoki, H., and Mouri, T. [Physiologically active compounds in the extracts from tochukaso and cultured mycelia of Cordyceps and Isaria]. Yakugaku Zasshi 1991;111(9):504-509. PubMed
  9. Wu, T. N., Yang, K. C., Wang, C. M., Lai, J. S., Ko, K. N., Chang, P. Y., and Liou, S. H. Lead poisoning caused by contaminated Cordyceps, a Chinese herbal medicine: two case reports. Sci.Total Environ. 4-5-1996;182(1-3):193-195. PubMed
  10. Hong T, Zhang M, Fan J. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients (Review). Cochrane Database Syst Rev. 2015;(10):CD009698. doi: 10.1002/14651858.CD009698.pub2.
  11. Zhang HW, Lin ZX, Tung YS, Kwan TH, Mok CK, Leung C, Chan LS. Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease (Review). Cochrane Database Syst Rev. 2014;(12):CD008353. doi: 10.1002/14651858.CD008353.pub2. PubMed
  12. Bee Yean O, Zoriah A. Efficacy of Cordyceps sinensis as an adjunctive treatment in hemodialysis patients: a systematic review and Meta-analysis. J Tradit Chin Med. 2019;39(1):1-14.
  13. Thurian D, Montani M, Stickel F. Drug-induced, mixed-type hepatitis following ingestion of Cordyceps sinensis. Int J Clin Pharmacol Ther 2022;60(2):115-120. PubMed
  14. Yu X, Mao Y, Shergis JL, et al. Effectiveness and safety of oral Cordyceps sinensis on stable COPD of GOLD stages 2-3: Systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:4903671.

See these in context on the Cordyceps monograph →

Reishi Mushroom 17 references
  1. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  2. Tao J, Feng KY. Experimental and clinical studies on inhibitory effect of ganoderma lucidum on platelet aggregation. J Tongji Med Univ 1990;10:240-3. PubMed
  3. Singh AB, Gupta SK, Pereira BM, Prakash D. Sensitization to Ganoderma lucidum in patients with respiratory allergy in India. Clin Exp Allergy 1995;25:440-7.
  4. Lee SY, Rhee HM. Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull (Tokyo) 1990;38:1359-64. PubMed
  5. Kwok Y, Ng KFJ, Li, CCF, et al. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 2005;101:423-6. PubMed
  6. Wanmuang, H., Leopairut, J., Kositchaiwat, C., Wananukul, W., and Bunyaratvej, S. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai. 2007;90(1):179-181.
  7. Seto, S. W., Lam, T. Y., Tam, H. L., Au, A. L., Chan, S. W., Wu, J. H., Yu, P. H., Leung, G. P., Ngai, S. M., Yeung, J. H., Leung, P. S., Lee, S. M., and Kwan, Y. W. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db
  8. Chu, T. T., Benzie, I. F., Lam, C. W., Fok, B. S., Lee, K. K., and Tomlinson, B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br.J.Nutr. 2012;107(7):1017-1027.
  9. Jin, X., Ruiz, Beguerie J., Sze, D. M., and Chan, G. C. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane.Database.Syst.Rev. 2012;6:CD007731.
  10. Kabir, Y., Kimura, S., and Tamura, T. Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol.(Tokyo) 1988;34(4):433-438. PubMed
  11. Kanmatsuse, K., Kajiwara, N., Hayashi, K., Shimogaichi, S., Fukinbara, I., Ishikawa, H., and Tamura, T. [Studies on Ganoderma lucidum. I. Efficacy against hypertension and side effects]. Yakugaku Zasshi 1985;105(10):942-947. PubMed
  12. Gao, Y., Lan, J., Dai, X., Ye, J., and Zhou, S. A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum(W.Curt: Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Type II Diabetes Mellitus. International Journal of Medicinal Mushrooms 2004;6. DOI
  13. Jin H, Zhang G, Cao X, and et al. Treatment of hypertension by linzhi combined with hypotensor and its effects on arterial, arteriolar and capillary pressure and microcirculation. In: Niimi H, Xiu RJ, Sawada T, and et al. Microcirculatory Approach to Asi
  14. Klupp NL, Chang D, Hawke F, Kiat H, Cao H, Grant SJ, Bensoussan A. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015 Feb 17;2:CD007259. PubMed
  15. Zhao H, Zhang Q, Zhao L, Huang X, Wang J, Kang X. Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial. Evid Based Complement Alternat Med. 2012;2012:809614.
  16. Pazzi F, Adsuar JC, Domínguez-Muñoz FJ, García-Gordillo MA, Gusi N, Collado-Mateo D. Ganoderma lucidum effects on mood and health-related quality of life in women with fibromyalgia. Healthcare (Basel) 2020;8(4):520. PubMed
  17. Kogure T, Koiwai A, Fukushi D, et al. Hypereosinophilia with hepatic nodule formation caused by Ganoderma lucidum. Intern Med 2021;60(24):3897-3903.

See these in context on the Reishi Mushroom monograph →

Agaricus Mushroom 5 references
  1. Hsu CH, Liao YL, Lin SC, et al. The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial. J Altern Complement Med 2
  2. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol 2006;36:808-10. PubMed
  3. Ohno S, Sumiyoshi Y, Hashine K, et al. Phase I clinical study of the dietary supplement, Agaricus blazei Murill, in cancer patients in remission. Evid Based Complement Alternat Med 2011, doi 10.1155/2011/192381.
  4. Suehiro M, Katoh N, Kishimoto S. Chelitis due to Agaricus blazei Murill mushroom extract. Contact Dermatitis 2007;56(5):293-4.
  5. Iwai N, Okuda T, Sawada R, et al. Interstitial lung disease associated with Agaricus blazei Murill in a patient with pancreatic ductal adenocarcinoma receiving gemcitabine-based therapy. Case Rep Gastroenterol 2022;16(1):229-234.

See these in context on the Agaricus Mushroom monograph →

Maitake Mushroom 8 references
  1. Kabir Y, Kimura S. Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo) 1989;35:91-4. PubMed
  2. Kabir Y, Yamaguchi M, Kimura S. Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 1987;33:341-6. PubMed
  3. Konno S, Tortorelis DG, Fullerton SA, et al. A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients. Diabet Med 2001;18:1010. PubMed
  4. Chen JT, Tominaga K, Sato Y, et al. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Altern Compl
  5. Hanselin MR, Vande Griend JP, Linnebur SA. INR elevation with maitake extract in combination with warfarin. Ann Pharmacother 2010;44:223-4. PubMed
  6. Talpur, N. A., Echard, B. W., Fan, A. Y., Jaffari, O., Bagchi, D., and Preuss, H. G. Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains. Mol.Cell Biochem. 2002;237(1-2):129-136. PubMed
  7. Deng, G., Lin, H., Seidman, A., Fornier, M., D'Andrea, G., Wesa, K., Yeung, S., Cunningham-Rundles, S., Vickers, A. J., and Cassileth, B. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: i
  8. Wesa KM, Cunningham-Rundles S, Klimek VM, et al. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother 2015;64(2):237-47. PubMed

See these in context on the Maitake Mushroom monograph →

Chaga 9 references
  1. Sun JE, Ao ZH, Lu ZM, et al. Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. J Ethnopharmacol 2008;118(1):7-13. PubMed
  2. Hyun KW, Jeong SC, Lee DH, et al. Isolation and characterization of a novel platelet aggregation inhibitory peptide from the medicinal mushroom, Inonotus obliquus. Peptides 2006;27(6):1173-8. PubMed
  3. Kim YO, Han SB, Lee HW, et al. Immuno-stimulating effect of the endo-polysaccharide produced by submerged culture of Inonotus obliquus. Life Sci 2005;77(19):2438-56. PubMed
  4. Kikuchi Y, Seta K, Ogawa Y, et al. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol 2014;81(6):440-4. PubMed
  5. Lee S, Lee HY, Park Y, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122.
  6. Kwon O, Kim Y, Paek JH, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report. Medicine (Baltimore) 2022;101(10):e28997. PubMed
  7. Su L, Xin C, Yang J, et al. A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus. Int J Biol Macromol 2022;214:312-323. PubMed
  8. Chen S, Ma Y, Li H, et al. Anti-diabetic e?ects of Inonotus obliquus extract in high fat diet combined streptozotocin-induced type 2 diabetic mice. Nutr Hosp 2022;39(6):1256-1263. PubMed
  9. Ye X, Wu K, Xu L, et al. Methanol extract of Inonotus obliquus improves type 2 diabetes mellitus through modifying intestinal flora. Front Endocrinol (Lausanne) 2023;13:1103972. PubMed

See these in context on the Chaga monograph →

Ashwagandha 32 references
  1. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  2. Upton R, ed. Ashwagandha Root (Withania somnifera): Analytical, quality control, and therapuetic monograph. Santa Cruz, CA: American Herbal Pharmacopoeia 2000:1-25.
  3. Davis L, Kuttan G. Effect of Withania somnifera on cyclophosphamide-induced urotoxicity. Cancer Lett 2000;148:9-17. PubMed
  4. Davis L, Kuttan G. Suppressive effect of cyclophosphamide-induced toxicity by Withania somnifera extract in mice. J Ethnopharmacol 1998;62:209-14. PubMed
  5. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 2000;5:334-46. DOI
  6. Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera, Dunal) root. Indian J Exp Biol 2000;38:607-9.
  7. Kulkarni RR, Patki PS, Jog VP, et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991;33:91-5. PubMed
  8. Ahumada F, Aspee F, Wikman G, Hancke J. Withania somnifera exract. Its effects on arterial blood pressure in anaesthetized dogs. Phytother Res 1991;5:111-14.
  9. Panda S, Kar A. Withania somnifera and Bauhinia purpurea in the regulation of circulating thyroid hormone concentrations in female mice. J Ethnopharmacol 1999;67:233-39. PubMed
  10. Panda S, Kar A. Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. J Pharm Pharmacol 1998;50:1065-68. PubMed
  11. Sehgal, V. N., Verma, P., and Bhattacharya, S. N. Fixed-drug eruption caused by ashwagandha (Withania somnifera): a widely used Ayurvedic drug. Skinmed. 2012;10(1):48-49.
  12. Agnihotri AP, Sontakke SD, Thawani VR, Saoji A, Goswami VS. Effects of Withania somnifera in patients of schizophrenia: a randomized, double blind, placebo controlled pilot trial study. Indian J Pharmacol. 2013;45(4):417-8. PubMed
  13. Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013;12(4):312-22.
  14. Sharma AK, Basu I, Singh S. Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. J Altern Complement Med. 2018 Mar;24(3):243-248. PubMed
  15. Durg S, Bavage S, Shivaram SB. Withania somnifera (Indian ginseng) in diabetes mellitus: A systematic review and meta-analysis of scientific evidence from experimental research to clinical application. Phytother Res. 2020;34(5):1041-1059.
  16. Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825-829. PubMed
  17. Tharakan A, Shukla H, Benny IR, Tharakan M, George L, Koshy S. Immunomodulatory Effect of Withania somnifera (Ashwagandha) Extract-A Randomized, Double-Blind, Placebo Controlled Trial with an Open Label Extension on Healthy Participants. J Clin Med 2021;1 PubMed
  18. Ireland PJ, Hardy T, Burt AD, Donnelly MC. Drug-induced hepatocellular injury due to herbal supplement ashwagandha. J R Coll Physicians Edinb. 2021;51(4):363-365. PubMed
  19. Kamal HI, Patel K, Brdak A, Heffernan J, Ahmad N. Ashwagandha as a unique cause of thyrotoxicosis presenting with supraventricular tachycardia. Cureus. 2022 Mar 25;14(3):e23494. PubMed
  20. Suryawanshi G, Abdallah M, Thomson M, Desai N, Chauhan A, Lim N. Ashwagandha-Associated Acute Liver Failure Requiring Liver Transplantation. Am J Ther 2023;30(1):e80-e83. PubMed
  21. Pusec CM, Wolsky R, Llerena C, Sura P. A Case of Supplement-Induced Hepatitis. Cureus 2022;14(10):e30433. PubMed
  22. Ajgaonkar A, Jain M, Debnath K. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract for Improvement of Sexual Health in Healthy Women: A Prospective, Randomized, Placebo-Controlled Study. Cureus 2022;14(10):e30787. PubMed
  23. Haron MH, Dale O, Martin K, et al. Evaluation of the Herb-Drug Interaction Potential of Commonly Used Botanicals on the US Market with Regard to PXR- and AhR-Mediated Influences on CYP3A4 and CYP1A2. J Diet Suppl 2022. PubMed
  24. Lubarska M, Halasinski P, Hryhorowicz S, et al. Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury. Int J Environ Res Public Health 2023;20(5):3921. PubMed
  25. Tóth M, Benedek AE, Longerich T, Seitz HK. Ashwagandha-induced acute liver injury: A case report. Clin Case Rep 2023;11(3):e7078.
  26. Bokan G, Glamocanin T, Mavija Z, et al. Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause. Pharmaceuticals (Basel) 2023;16(8):1129. PubMed
  27. Patel PA, Sanborn E, Then R, Williams DM. Recurrent Reversible Cerebral Vasoconstriction Syndrome: A Report of Two Cases. Cureus 2023;15(8):e42992. PubMed
  28. Majeed M, Nagabhushanam K, Murali A, Vishwanathan DT, Mamidala RV, Mundkur L. A Standardized Withania somniferra (Linn.) Root Extract with Piperine Alleviates the Symptoms of Anxiety and Depression by Increasing Serotonin Levels: A Double-Blind, Randomize
  29. Philips CA, Valsan A, Theruvath AH, et al. Ashwagandha-induced liver injury-A case series from India and literature review. Hepatol Commun 2023;7(10):e0270. PubMed
  30. Hayashi M, Hamada H, Azuma SI, Hayashi K. Painless Thyroiditis by Withania somnifera (Ashwagandha). Cureus 2024;16(3):e55352. PubMed
  31. Vazirani S, Kothari A, Fujimoto J, Gomez M. Supplements Are Not a Synonym for Safe: Suspected Liver Injury From Ashwagandha. Fed Pract 2023;40(9):315-319. PubMed
  32. Patel M, Newell R, Hillier M, Ramalingam R. Herbal remedies as a potential cause of hypoadrenalism. Br J Hosp Med (Lond) 2024;85(6):1-4. PubMed

See these in context on the Ashwagandha monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring